Smith+Nephew Signs Exclusive Distribution Agreement with RMR Ortho
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy SNN?
Smith+Nephew announces it has signed an exclusive U.S. distribution agreement with RMR Ortho to add the A'TOMIC Nitinol Fixation System to the Smith+Nephew Trauma, Foot & Ankle and Hand & Wrist portfolio. "This partnership with RMR Ortho strengthens Smith+Nephew's fixation portfolio by adding a dynamic compression fixation solution that complements our existing technologies," said Scott Gunn, Vice President of U.S. Marketing, Trauma, Extremities, and Shoulder at Smith+Nephew. "The A'TOMIC Nitinol Fixation System expands our ability to participate in high-frequency fracture and arthrodesis procedures while leveraging our established Extremities and Trauma sales channel to deepen surgeon engagement. This collaboration reflects our disciplined approach to portfolio expansion and our continued focus on driving sustainable growth."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNN
Wall Street analysts forecast SNN stock price to fall
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 36.900
Low
34.00
Averages
35.75
High
37.50
Current: 36.900
Low
34.00
Averages
35.75
High
37.50
About SNN
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Smith & Nephew Reports Significant Profit Increase in Fiscal 2025
- Significant Profit Growth: In fiscal 2025, Smith & Nephew's profit before tax surged to $779 million from $498 million, indicating strong performance in the medical technology sector, which is likely to boost investor confidence.
- Earnings Per Share Increase: Earnings per share rose to 71.6 cents, up from 47.0 cents last year, while adjusted earnings per share increased from 84.3 cents to 102.0 cents, reflecting the company's sustained profitability enhancement.
- Steady Revenue Growth: Total revenue grew by 6.1% to $6.16 billion, with fourth-quarter revenue reaching $1.70 billion, an 8.3% increase year-over-year, demonstrating the company's increasing competitiveness in the market.
- Dividend Increase: The Board proposed a final dividend of 24.1 cents per share, up by 1 cent from last year, with a total annual distribution of 39.1 cents, showcasing the company's confidence in future profitability and commitment to shareholder returns.
See More
Smith+Nephew Showcases Rotator Cuff Repair Technologies
- Market Potential: With approximately 500,000 rotator cuff repair procedures performed annually in the U.S., Smith+Nephew's new technologies aim to reduce the 20-40% failure rates associated with traditional surgeries, enhancing the company's competitive edge in this rapidly growing market.
- Innovative Technology: The Tendon Seam introduces a unique biomechanical repair technique alongside the REGENETEN Bioinductive Implant, designed to improve early recovery outcomes by enhancing tendon integrity, thereby driving differentiation in the medical technology sector.
- Clinical Validation: Since its introduction in 2014, the REGENETEN Bioinductive Implant has been used in over 250,000 procedures globally, with clinical trial data demonstrating superior repair outcomes compared to traditional methods, further solidifying Smith+Nephew's market position.
- Industry Recognition: The AAOS's newly published Clinical Practice Guideline supports the use of bioinductive implants, highlighting their value in rotator cuff repair, which is expected to increase market acceptance and application of this technology, boosting the company's future sales potential.
See More
Smith+Nephew Showcases Rotator Cuff Repair Technology
- Significant Market Potential: With approximately 500,000 rotator cuff repair procedures performed annually in the U.S. and traditional surgical techniques experiencing structural failure rates of 20-40%, Smith+Nephew's innovative technologies present a substantial market opportunity.
- Technological Innovation: The newly acquired Tendon Seam technology employs a unique biomechanical repair method alongside the market-leading REGENETEN Bioinductive Implant, aiming to reduce re-tear rates and improve patient outcomes, thereby differentiating itself in a competitive landscape.
- Clinical Practice Guideline Support: The American Academy of Orthopaedic Surgeons has issued a strong recommendation for the use of bioinductive implants in rotator cuff repair, highlighting their effectiveness in lowering re-tear rates and enhancing patient-reported outcomes, which further drives market acceptance.
- Global Impact: Since its introduction in 2014, the REGENETEN Bioinductive Implant has been involved in over 250,000 procedures globally, demonstrating its transformative impact on patients with rotator cuff injuries and underscoring Smith+Nephew's leadership in the medical technology sector.
See More
Smith & Nephew Reports Q4 Revenue Growth of 8.3%
- Revenue Beats Expectations: Smith & Nephew reported Q4 revenue of $1.7 billion, reflecting an 8.3% year-over-year growth that exceeded market expectations by $20 million, indicating robust performance in the medical device sector.
- Strong Orthopaedics Performance: The Orthopaedics division achieved an underlying revenue growth of 7.9% (reported growth of 9.8%), marking the strongest quarterly growth in over two years, suggesting a rebound in market demand and enhanced product competitiveness.
- Acquisition Impact: The completion of the Integrity Orthopaedics acquisition is expected to have a marginally dilutive effect on trading profit in 2026, but is projected to be broadly neutral in 2027 and accretive by 2028, reflecting the company's confidence in future growth.
- Optimistic Future Outlook: For 2026, underlying revenue growth is expected to accelerate to around 6%, with trading profit growth anticipated at approximately 8%, alongside a commitment to achieving an adjusted ROIC exceeding 10%, demonstrating strategic determination in sustaining strong cash generation.
See More
CMA Launches Investigation into Hotel Competition
- Investigation Launched: The UK's Competition and Markets Authority (CMA) has initiated an investigation into Intercontinental Hotels, Hilton, and Marriott over suspected sharing of sensitive commercial information via a data provider, potentially violating the Competition Act 1998, which could significantly impact their operations if proven unlawful.
- Strong Financial Performance: Smith & Nephew reported a robust finish to 2025, with fourth-quarter revenue rising 8.3% to $1.7 billion and full-year revenue increasing 6.1% to $6.2 billion, alongside a 20.7% rise in operating profit to $794 million, reflecting confidence in future growth post turnaround plan.
- Stable House Prices: According to Nationwide, house price growth remained steady in February at an annual rate of 1.0% and a monthly increase of 0.3%, with the average home costing £273,176, indicating a modest recovery in the housing market amid pre-Budget uncertainties, as first-time buyer mortgage completions rose by 18%.
- Muted Market Reaction: Despite rising oil and gas prices due to tensions in the Middle East, market analysts noted a relatively muted response in financial markets, with the FTSE 100 expected to open 85 points lower, although defense stocks may surge, reflecting cautious sentiment amid potential risks.
See More
Smith+Nephew Signs Exclusive US Distribution Agreement with RMR Ortho
- Exclusive Distribution Agreement: Smith+Nephew has signed an exclusive agreement with RMR Ortho to incorporate the A'TOMIC™ Nitinol Fixation System into its Trauma, Foot & Ankle, and Hand & Wrist portfolio, aiming to enhance implant integrity and patient comfort, thereby strengthening market competitiveness.
- Portfolio Expansion: The system adds a dynamic compression fixation solution to Smith+Nephew's offerings, expected to increase its market participation in high-frequency fracture and arthrodesis procedures, further deepening engagement with surgeons.
- Manufacturing Technology Advantage: The A'TOMIC™ Nitinol Fixation System leverages proprietary manufacturing methods and the unique properties of nitinol to provide high-strength, actively compressive implants that ensure stability at fusion, fracture, and osteotomy sites, enhancing surgical success rates.
- Strategic Market Partnership: RMR Ortho CEO Joe Ritz noted that partnering with Smith+Nephew will expand access to the A'TOMIC system across the U.S., utilizing Smith+Nephew's established relationships and commercial scale to promote reliable fixation solutions.
See More
Smith & Nephew Reports Significant Profit Increase in Fiscal 2025
- Significant Profit Growth: In fiscal 2025, Smith & Nephew's profit before tax surged to $779 million from $498 million, indicating strong performance in the medical technology sector, which is likely to boost investor confidence.
- Earnings Per Share Increase: Earnings per share rose to 71.6 cents, up from 47.0 cents last year, while adjusted earnings per share increased from 84.3 cents to 102.0 cents, reflecting the company's sustained profitability enhancement.
- Steady Revenue Growth: Total revenue grew by 6.1% to $6.16 billion, with fourth-quarter revenue reaching $1.70 billion, an 8.3% increase year-over-year, demonstrating the company's increasing competitiveness in the market.
- Dividend Increase: The Board proposed a final dividend of 24.1 cents per share, up by 1 cent from last year, with a total annual distribution of 39.1 cents, showcasing the company's confidence in future profitability and commitment to shareholder returns.
See More
Smith+Nephew Showcases Rotator Cuff Repair Technologies
- Market Potential: With approximately 500,000 rotator cuff repair procedures performed annually in the U.S., Smith+Nephew's new technologies aim to reduce the 20-40% failure rates associated with traditional surgeries, enhancing the company's competitive edge in this rapidly growing market.
- Innovative Technology: The Tendon Seam introduces a unique biomechanical repair technique alongside the REGENETEN Bioinductive Implant, designed to improve early recovery outcomes by enhancing tendon integrity, thereby driving differentiation in the medical technology sector.
- Clinical Validation: Since its introduction in 2014, the REGENETEN Bioinductive Implant has been used in over 250,000 procedures globally, with clinical trial data demonstrating superior repair outcomes compared to traditional methods, further solidifying Smith+Nephew's market position.
- Industry Recognition: The AAOS's newly published Clinical Practice Guideline supports the use of bioinductive implants, highlighting their value in rotator cuff repair, which is expected to increase market acceptance and application of this technology, boosting the company's future sales potential.
See More
Smith+Nephew Showcases Rotator Cuff Repair Technology
- Significant Market Potential: With approximately 500,000 rotator cuff repair procedures performed annually in the U.S. and traditional surgical techniques experiencing structural failure rates of 20-40%, Smith+Nephew's innovative technologies present a substantial market opportunity.
- Technological Innovation: The newly acquired Tendon Seam technology employs a unique biomechanical repair method alongside the market-leading REGENETEN Bioinductive Implant, aiming to reduce re-tear rates and improve patient outcomes, thereby differentiating itself in a competitive landscape.
- Clinical Practice Guideline Support: The American Academy of Orthopaedic Surgeons has issued a strong recommendation for the use of bioinductive implants in rotator cuff repair, highlighting their effectiveness in lowering re-tear rates and enhancing patient-reported outcomes, which further drives market acceptance.
- Global Impact: Since its introduction in 2014, the REGENETEN Bioinductive Implant has been involved in over 250,000 procedures globally, demonstrating its transformative impact on patients with rotator cuff injuries and underscoring Smith+Nephew's leadership in the medical technology sector.
See More
Smith & Nephew Reports Q4 Revenue Growth of 8.3%
- Revenue Beats Expectations: Smith & Nephew reported Q4 revenue of $1.7 billion, reflecting an 8.3% year-over-year growth that exceeded market expectations by $20 million, indicating robust performance in the medical device sector.
- Strong Orthopaedics Performance: The Orthopaedics division achieved an underlying revenue growth of 7.9% (reported growth of 9.8%), marking the strongest quarterly growth in over two years, suggesting a rebound in market demand and enhanced product competitiveness.
- Acquisition Impact: The completion of the Integrity Orthopaedics acquisition is expected to have a marginally dilutive effect on trading profit in 2026, but is projected to be broadly neutral in 2027 and accretive by 2028, reflecting the company's confidence in future growth.
- Optimistic Future Outlook: For 2026, underlying revenue growth is expected to accelerate to around 6%, with trading profit growth anticipated at approximately 8%, alongside a commitment to achieving an adjusted ROIC exceeding 10%, demonstrating strategic determination in sustaining strong cash generation.
See More
CMA Launches Investigation into Hotel Competition
- Investigation Launched: The UK's Competition and Markets Authority (CMA) has initiated an investigation into Intercontinental Hotels, Hilton, and Marriott over suspected sharing of sensitive commercial information via a data provider, potentially violating the Competition Act 1998, which could significantly impact their operations if proven unlawful.
- Strong Financial Performance: Smith & Nephew reported a robust finish to 2025, with fourth-quarter revenue rising 8.3% to $1.7 billion and full-year revenue increasing 6.1% to $6.2 billion, alongside a 20.7% rise in operating profit to $794 million, reflecting confidence in future growth post turnaround plan.
- Stable House Prices: According to Nationwide, house price growth remained steady in February at an annual rate of 1.0% and a monthly increase of 0.3%, with the average home costing £273,176, indicating a modest recovery in the housing market amid pre-Budget uncertainties, as first-time buyer mortgage completions rose by 18%.
- Muted Market Reaction: Despite rising oil and gas prices due to tensions in the Middle East, market analysts noted a relatively muted response in financial markets, with the FTSE 100 expected to open 85 points lower, although defense stocks may surge, reflecting cautious sentiment amid potential risks.
See More
Smith+Nephew Signs Exclusive US Distribution Agreement with RMR Ortho
- Exclusive Distribution Agreement: Smith+Nephew has signed an exclusive agreement with RMR Ortho to incorporate the A'TOMIC™ Nitinol Fixation System into its Trauma, Foot & Ankle, and Hand & Wrist portfolio, aiming to enhance implant integrity and patient comfort, thereby strengthening market competitiveness.
- Portfolio Expansion: The system adds a dynamic compression fixation solution to Smith+Nephew's offerings, expected to increase its market participation in high-frequency fracture and arthrodesis procedures, further deepening engagement with surgeons.
- Manufacturing Technology Advantage: The A'TOMIC™ Nitinol Fixation System leverages proprietary manufacturing methods and the unique properties of nitinol to provide high-strength, actively compressive implants that ensure stability at fusion, fracture, and osteotomy sites, enhancing surgical success rates.
- Strategic Market Partnership: RMR Ortho CEO Joe Ritz noted that partnering with Smith+Nephew will expand access to the A'TOMIC system across the U.S., utilizing Smith+Nephew's established relationships and commercial scale to promote reliable fixation solutions.
See More
